Last reviewed · How we verify
CLBS12
CLBS12 is a cell therapy product that aims to repair or replace damaged heart tissue.
CLBS12 is a cell therapy product that aims to repair or replace damaged heart tissue. Used for Treatment of heart failure.
At a glance
| Generic name | CLBS12 |
|---|---|
| Also known as | CD34+ cells |
| Sponsor | Lisata Therapeutics, Inc. |
| Drug class | cell therapy |
| Modality | Biologic |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
CLBS12 is a type of regenerative medicine that utilizes a patient's own cells to promote cardiac repair. This is achieved through a process where the patient's own cells are collected, processed, and then reinfused into the heart to stimulate the growth of new tissue and improve cardiac function.
Approved indications
- Treatment of heart failure
Common side effects
- Flu-like symptoms
- Fatigue
- Pain at injection site
Key clinical trials
- Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CLBS12 CI brief — competitive landscape report
- CLBS12 updates RSS · CI watch RSS
- Lisata Therapeutics, Inc. portfolio CI